← Back to Search

Smoking Cessation Program in the Preadmission Clinic

Phase 4
Waitlist Available
Led By Frances Chung, FRCPC
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
Approved for 5 Other Conditions
All Individual Drugs Already Approved

Summary

This study is a randomized, double-blind, placebo-controlled clinical trial which evaluates the efficacy of preoperative smoking counseling and varenicline (a medication approved by Health Canada and FDA for quitting smoking) to provide long term smoking cessation (i.e., abstinence for at least one year) in surgical patients. The primary hypothesis is as follows: "A significant percentage of surgical patients will be receptive to smoking cessation interventions in the pre-admission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment." The secondary hypothesis is as follows: "Patients who receive interventions but do not quit smoking will have reduced number of cigarettes consumed/day or improved their readiness to quit smoking at 24 and 52 weeks after starting the treatment."

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Smoking counseling, VareniclineExperimental Treatment2 Interventions
Group II: Smoking counseling, PlaceboPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Smoking counseling
2015
N/A
~40
Varenicline
FDA approved

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,670 Previous Clinical Trials
17,826,641 Total Patients Enrolled
11 Trials studying Smoking
3,264 Patients Enrolled for Smoking
University Health Network, TorontoLead Sponsor
1,531 Previous Clinical Trials
504,133 Total Patients Enrolled
3 Trials studying Smoking
696 Patients Enrolled for Smoking
Frances Chung, FRCPCPrincipal InvestigatorAnesthesia Department, Toronto Western Hospital, University of Toronto
2 Previous Clinical Trials
416 Total Patients Enrolled
1 Trials studying Smoking
296 Patients Enrolled for Smoking
~17 spots leftby Dec 2025